Related Experiment Videos
[Beta-endorphin in acute focal cerebral infarct]
Medicina Clinica
|September 16, 1989
Summary
Patients with acute focal cerebral infarct (AFCI) show lower beta-endorphin and corticotropin (ACTH) levels. Further research is needed to understand the role of these opioids in AFCI before considering naloxone therapy.
Area of Science:
- Neuroscience
- Endocrinology
Context:
- Animal studies suggest endorphin system involvement in cerebral ischemia.
- Naloxone shows promise in animal models but clinical trial results are conflicting.
- The significance of elevated beta-endorphin in acute focal cerebral infarct (AFCI) remains unclear.
Purpose:
- To evaluate plasma beta-endorphin and corticotropin (ACTH) levels in patients with AFCI.
- To compare these levels with a control group and assess changes over time.
Summary:
- 23 AFCI patients had significantly lower plasma beta-endorphin and ACTH levels compared to controls within 48 hours of onset.
- A subgroup of 9 patients showed a moderate, non-significant increase in beta-endorphin after 7 days.
- Infarct size and location did not correlate with beta-endorphin levels.
Impact:
- Findings suggest that plasma beta-endorphin levels may need consideration before prescribing naloxone for AFCI.
- Establishes the need to confirm if plasma beta-endorphin changes reflect cerebral alterations.
- Highlights the unestablished pathophysiological role of opioids in AFCI.